Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,982 public trials 2,028 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

NCT00963534

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Århus University Hospital Aarhus, Denmark
  • Herlev Hospital Copenhagen, Denmark
  • Rigshospitalet, Department of Hematology Copenhagen, Denmark
  • Helsinki University Central Hospital Helsinki, Finland
View all 17 locations
View Trial Details
Completed

Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL

NCT01737177

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • UOC Ematologia Trani Trani, Barletta-Andria-Trani (BT), Italy
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST Meldola Meldola, Forlì Cesena, Italy
  • Ematologia Istituto Clinico Humanitas Rozzano, Milano, Italy
  • Centro di riferimento Oncologico CRO Aviano Aviano, Pordenone, Italy
View all 43 locations
View Trial Details
Completed

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

NCT00299494

Conditions
B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • University of Alabama at Birmingham- Birmingham, Alabama, United States
  • IDS Pharmacy Birmingham, Alabama, United States
  • University of Alabama at Birmingham- Birmingham, Alabama, United States
  • California Cancer Care, Inc. Greenbrae, California, United States
View all 38 locations
View Trial Details
Completed

Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

NCT00253630

Conditions
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hemic and Lymphatic Diseases, Immune System Diseases, +17 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
View Trial Details
Completed

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

NCT01365559

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Pacific Oncology and Hematology Encinitas, California, United States
  • Pacific Cancer Care Salinas, California, United States
  • Central Coast Medical Oncology Santa Maria, California, United States
  • James R. Berenson, MD, Inc. West Hollywood, California, United States
View Trial Details

Related conditions